Represents largest dd-cfDNA retransplant study to date and demonstrates clinical value of proprietary background cfDNA technology SAN CARLOS, Calif. , Oct. 21, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced it will present
Celebrities and the public are making creative golf trick shot videos to create awareness and encourage donations for kidney disease patients SAN CARLOS , Calif. and LOS ANGELES , Oct. 5, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced
Upholds validity of Natera's patents; patent case against ArcherDX continues SAN CARLOS, Calif. , Oct. 5, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today reports that the U.S. District Court of Delaware has rejected all of ArcherDX's
SAN CARLOS, Calif. , Oct. 2, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA, today announced that its Signatera molecular residual disease (MRD) test will be used in the DARE study, a multi-center clinical trial of palbociclib (IBRANCE®), a CDK4/6
Proposes expanded coverage of the Signatera minimal residual disease (MRD) test in a broad range of solid tumor types and indications including immunotherapy (IO) monitoring SAN CARLOS, Calif. , Sept. 24, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free
1 oral and 3 poster presentations demonstrate effectiveness of Signatera™ in stage IV oligometastatic colorectal cancer (CRC), stage I-III CRC, and esophageal adenocarcinomas SAN CARLOS, Calif. , Sept. 18, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free
Innovative technology platform for cell-free DNA testing in oncology and organ transplantation uniquely positions Natera to help improve outcomes for the most vulnerable transplant patients SAN CARLOS, Calif. , Sept. 14, 2020 /PRNewswire/ -- Natera, Inc.
SAN CARLOS, Calif. , Sept. 11, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that Noridian, the Medicare Administrative Contractor (MAC) for Northern California , has finalized a final local coverage article (LCA) to provide
SAN CARLOS, Calif. , Sept. 10, 2020 /PRNewswire/ -- Natera, Inc . (Nasdaq: NTRA), a global leader in cell-free DNA testing, today announced the pricing of its underwritten public offering of 4,166,666 shares of its common stock at a price to the public of $60.00 per share.
SAN CARLOS, Calif. , Sept. 10, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced it will webcast a live presentation at the Morgan Stanley 18th Annual Global Healthcare Conference taking place virtually on Monday, Sept.
